




PHARMACEUTICAL 2021

Seres Therapeutics Inc.
Rank 222 of 402





RealRate

PHARMACEUTICAL 2021

Seres Therapeutics Inc.
Rank 222 of 402



The relative strengths and weaknesses of Seres Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Seres Therapeutics Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 23% points. The greatest weakness of Seres Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 81% points.

The company's Economic Capital Ratio, given in the ranking table, is 83%, being 35% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	268,777
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	46,415
Liabilities, Non-Current	11,564
Other Assets	60,266
Other Compr. Net Income	-47
Other Expenses	0
Other Liabilities	110,211
Other Net Income	-997
Other Revenues	33,215
Property and Equipment	13,897
Research and Development	90,570
Selling, General and Administrative Expense	30,775

Output Variable	Value in 1000 USD
Assets	342,940
Liabilities	168,190
Expenses	121,345
Revenues	33,215
Stockholders Equity	174,750
Net Income	-89,127
Comprehensive Net Income	-89,150
Economic Capital Ratio	83%